Search results
Author(s):
Giuseppe Rosano
,
Richard Henry P Tiongco
,
Rungroj Krittayaphong
,
et al
Start date:
Oct 05, 2022
View more
Author(s):
John JV McMurray
Added:
1 year ago
ESC Congress – Prof John McMurray (University of Glasgow, UK) joined us to discuss the finding of the PERSPECTIVE trial (NCT02884206).
The trial assessed whether the angiotensin receptor-neprilysin inhibitor (ARNi), sacubitril/valsartan (Novartis) has any negative impact on cognitive function in people who have heart failure with preserved ejection fraction (HFpEF) when compared with HFpEF…
View more
Author(s):
James L Januzzi
Added:
1 year ago
HFSA 22 - Dr James Januzzi (Massachusetts General Hospital, US) outlines the findings of the PROVE-HF study, a trial which aimed to determine the effect of sacubitril/valsartan therapy on cardiac biomarkers in patients with mitral regurgitation in heart failure with reduced ejection fraction.
Questions:
1. What was the ideology behind PROVE-HF?
2. What is the mechanism of action behind…
View more
Author(s):
Robert Mentz
,
Harriette Van Spall
Added:
10 months ago
ESC-HFA 2023 — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sits down with PI, Dr Robert J Mentz (Duke University of Medicine, US) to discuss the findings of the PARAGLIDE-HF trial (NCT03988634).
The PARAGLIDE-HF aimed to evaluate the effects of sacubitril/valsartan compared to valsartan on changes in NT-proBNP, safety and tolerability in HFpEF patients who have…
View more
Author(s):
Amarinder Bindra
,
Shelley A Hall
Added:
3 years ago
After a drought in viable new therapies for more than a decade, two new drugs for use in heart failure patients were approved by the US Food and Drug Administration (FDA) in 2015. These drugs represent two new classes of agents in the heart failure space: a combined angiotensin receptor-neprilysin inhibitor (ARNI) (sacubitril/valsartan; brand name Entresto®, Novartis) and a sinoatrial node…
View more
Author(s):
Michelle Kittleson
Added:
3 years ago
Decades ago heart failure (HF) was primarily regarded as a hemodynamic disorder in an attempt to explain patients’ symptoms and disability. This hemodynamic model led to the widespread evaluation of peripheral vasodilators (to increase cardiac output by decreasing systemic vascular resistance against the failing heart). It also led to the development of novel positive inotropic agents (to…
View more
Author(s):
Harriette Van Spall
,
Douglas L Mann
Added:
2 years ago
Dr Douglas Mann (Washington University School of Medicine, Missouri, US) meets host Dr Harriette Van Spall (McMaster University, Hamilton, CA) to discuss the findings from the Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection FractionTrial.
The LIFE trial aimed to address a knowledge gap regarding the efficacy, safety, and tolerability of sacubitril/valsartan in advanced HFrEF…
View more
Author(s):
Giuseppe Galati
Added:
3 years ago
Dr Giuseppe Galati (San Raffaele Scientific Institute, Milan, IT) comments on the PARALLAX trial. Dr Galati compares the ESC hotline trial with PARAGON-HF.The PARALLAX study showed potential benefits from sacubitril/valsartan in heart failure with preserved ejection fraction.
Recorded remotely from Milan, 2020.
Recording Editors: Natascha Wienand & Tom Green
Editor: Mirjam Boros
View more
Author(s):
William T Abraham
Added:
1 year ago
HFSA 2022 — Dr William T Abraham (The Ohio State University, US) talks about a study assessing a remote speech analysis application, Cordio app (Cordio Medical) that evaluated hospitalized patients with acute decompensated heart failure (NCT03266029).
Questions
What is the background of this study?
What is the Cordio app and what is the premise behind the HearO System?
What is the study design…
View more
Antoni Martínez-Rubio
Research Area(s) / Expertise:
Author